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Temozolomide resistance in glioblastoma cells occurs
partly through epidermal growth factor receptor-
mediated induction of connexin 43
JL Munoz1,2, V Rodriguez-Cruz2, SJ Greco2, SH Ramkissoon3,4, KL Ligon3,4 and P Rameshwar*,2
Glioblastoma Multiforme (GBM) is an aggressive adult primary brain tumor with poor prognosis. GBM patients develop resistance
to the frontline chemotherapy, temozolomide (TMZ). As the connexins (Cx) have been shown to have a complex role in GBM,
we investigated the role of Cx43 in TMZ resistance. Cx43 was increased in the TMZ-resistant low passage and cell lines. This
correlated with the data in The Cancer Genome Atlas. Cx43 knockdown, reporter gene assays, chromatin immunoprecipitation
assay, real-time PCR and western blots verified a role for Cx43 in TMZ resistance. This occurred by TMZ-resistant GBM cells being
able to activate epidermal growth factor receptor (EGFR). In turn, EGFR activated the JNK-ERK1/2-AP-1 axis to induce Cx43.
The increased Cx43 was functional as indicated by gap junctional intercellular communication among the resistant GBM cells.
Cell therapy could be a potential method to deliver drugs, such as anti-EGF to tumor cells. Similar strategies could be used to
reverse the expression of Cx43 to sensitize GBM cells to TMZ. The studies showed the potential for targeting EGF in immune
therapy. These agents can be used in conjunction with stem cell therapy to treat GBM.
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Glioblastoma Multiforme (GBM), the most common adult
primary brain tumor, has poor prognosis witho3% survival
after 5 years of diagnosis.1 Currently, anti-neoplastic
treatment combines chemotherapy, temozolomide (TMZ),
radiotherapy and resectional surgery.2 TMZ is an alkylating
agent that induces apoptosis through DNA strand breaks is
considered as the frontline chemotherapeutic agent for
GBM.3 Despite its frontline status, GBM patients commonly
exhibit resistance to TMZ treatment.4 Although there are
several reports aimed at understanding how GBM cells
resist TMZ, the mechanism(s) remain unclear. The reports
on chemoresistance include mismatch repair of genes, cell
cycle alterations and the expression of ATP-dependent drug
efflux pumps.5
A number of intracellular pathways have been described in
the growth and survival of GBM. These include the activation
of epidermal growth factor receptor (EGFR) in GBM cells.
EGFR dysfunction correlates with poor prognosis.6,7 GBM
patients with increased EGFR expression have enhanced
activation of the EGFR variant, EGFRvIII.8 The EGFR is a
member of the Erb family of receptor tyrosine kinases.
Activated EGFR is a homodimeric transmembrane protein
that undergoes auto-transphosphorylation through intrinsic
intracellular protein-tyrosine kinase domains.9 The activation
of EGFR leads to downstream signaling pathways such as
phosphorylation of AKT, MAPK and JNK.10
Chemoresistance of GBM cells can occur by intercellular
communication through gap junction (GJIC).11 GJIC is
established by the interaction between two hemichannels on
adjacent cell membranes.12 The hemichannels are formed by
members of the connexin (Cx) protein family. GJIC facilitates
the exchange of small molecules and microRNA.13,14 Cx43
can exert both tumor suppressor and oncogenic functions.15
Astrocytes and astrocytomas express high levels of Cx43.16
During epithelial-to-mesenchymal transition and the period of
overt tumor infiltration, there is a loss of GJIC between the
malignant cells.17 However, the role of Cx43 in the migration
of GBM cells is mixed. While the literature reported on a
requirement for decreased Cx43 for GBM cells to migrate to
other sites,17 another study showed a facilitating role for Cx43
in GBM migration.18 Together, these two opposing reports
underscored the complex role of Cx43 in the development of
GBM. This study investigated the role of GJIC in the early
phase of acquired chemoresistance.
Here we show an increase in Cx43 in TMZ-resistant GBM
cells that formed GJIC between the resistant cells. This
suggested that GJIC could be amethod by which resistance is
communicated among GBM cells. We demonstrated that
Cx43 expression was regulated at the level of transcription in
the chemoresistant GBM cells. This occurred partly through
the activation of EGFR1 that activated AP-1 to increase Cx43
transcription.
1Rutgers-Graduate School of Biomedical Science, Newark, NJ, USA; 2Department of Medicine, Hematology/Oncology, New Jersey Medical School, Rutgers School of
Biomedical Health Sciences, Newark, NJ, USA; 3Department of Pathology, Brigham and Women’s Hospital, Boston Children’s Hospital and Harvard Medical School,
Boston, MA, USA and 4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
*Corresponding author: P Rameshwar, Department of Medicine, Hematology/Oncology, New Jersey Medical School, Rutgers School of Biomedical Health Sciences,
185 South Orange Avenue, MSB E-585, Newark, NJ 07103, USA. Tel: þ 1 973 972 0625; Fax: þ 1 973 972 8854; E-mail: rameshwa@njms.rutgers.edu
Received 15.10.13; revised 07.2.14; accepted 17.2.14; Edited by Y Shi
Keywords: connexin 43; glioblastoma; resistance; temozolomide EGF receptor; stem cell; immune therapy
Abbreviations: Cx, connexin; Cx43, connexin 43; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; GBM, glioblastoma; Gja1, connexin
43–deficient mice; GJIC, gap junctional intercellular communication; TCGA, The Cancer Genome Atlas; TMZ, temozolomide
Citation: Cell Death and Disease (2014) 5, e1145; doi:10.1038/cddis.2014.111
& 2014 Macmillan Publishers Limited All rights reserved 2041-4889/14
www.nature.com/cddis
Results
Cx43 expression in TMZ-resistant GBM cells. The role of
GJIC has been extensively studied in the central nervous
system.19 We asked whether TMZ resistance could be
‘transmitted’ to other cells through GJIC. We first identified
the Cx type on TMZ-resistant U87 and T98G cells.
Chemoresistance was established with 200 mM TMZ for
72 h.20 The viable cells were studied for Cx expression by
real-time PCR and western blot. We selected Cx26, Cx32
and Cx43 because of their expression on neurons, Schwann
cells and astrocytes, respectively.19 Cx43 mRNA was
increased by four- to six–fold and its protein was increased
by three- to four-fold; Cx26 mRNA was minimally increased
and Cx32 mRNA was undetectable (CT435) (Figures 1a
and b). Similar findings were noted for the corresponding
proteins (Figure 2b). In summary, Cx43 expression was
significantly increased in the TMZ-resistant GBM cells.
As commercial U87 and T98G were passaged for many
generations, we asked whether Cx was similarly expressed in
primary GBM cells, low-passage GBM cells from patients with
naive (BT145) and recurring (resistant) (BT164) GBM. Real-
time PCR for Cx26, Cx32 and Cx43 cDNA indicated
significant (Po0.05) increases in BT164 (resistant) as
compared with BT145 (naive) (Figure 1c). Western blot
indicated a significant increase for Cx43 in the resistant
BT164 cells but reduced Cx26 and undetectable Cx32
(Figure 1d).
We next analyzed the data in The Cancer Genome Atlas
(TCGA) to determine whether Cx43 is increased in a large
number of GBM tissues. The TCGA project has data analyzed
using Agilent Gene Chip with 4500 primary GBM tissues.
Comparative analyses for Cx43 expression were performed
with the 522 available gene chip data, showed Cx43
expression with a Z-score of 2.7 and a S.D. of 1.3. This
indicated an average of 2.7-fold increase in Cx43 expression
in the GBM samples as compared with control gene
expression. Similar analyses for Cx26 and Cx32 showed no
significant (P40.05) change as compared with control
(Figure 1e). Taken together, TMZ-resistant GBM cells,
including the low-passaged cell lines, combined with the data
in the TCGA gene array database, which indicated that Cx43
was increased in GBM.
Sensitization of Cx43 knockdown GBM cells to TMZ.
The studies supported a molecular role for Cx43 in TMZ
resistance GBM cells (Figure 1). Functional studies investi-
gated the sensitivity of GJA1 (Cx43) knockdown GBM cells.
The specificity was studied with non-targeted siRNA (nega-
tive control). Real-time PCR and western blot verified the
efficiency of Cx43 knockdown (Figures 2a and b,
Supplementary Figure S1). GBM cells were established as
resistance to TMZ by treating with 200mM TMZ. At 72h, the
cells were analyzed with a LHD release assay for cell death.
As expected, only the resistant cells survived TMZ treatment
in the untransfected cells, shown as B35% (Figure 2c,
untransfected). There was no significant difference (P40.05)
with a non-targeting siRNA. In contrast, transfection with
Cx43 siRNA caused a significant (Po0.05) increase in cell
death as compared with cells transfected with non-targeting
siRNA (Figure 2c). These findings indicated that Cx43 was
involved in the acquired resistance of TMZ-treated GBM
cells.
TMZ activated the 50 regulatory region of GJA1 (Cx43) in
GBM cells. Figures 1 and 2 supported the involvement of
Cx43 in TMZ resistance. We asked if this occurs by induced
Cx43. We used a reporter gene system with four different
fragments of the 50 regulatory region of Cx43. U87 and T98G
were transfected with the reporter gene vectors containing
250, 350, 400 and 1400 bp upstream of the translational start
site.21 Controls were transfected with vector alone. After
24 h, the transfectants were treated with 200mM TMZ or
vehicle. At 72 h, whole-cell extracts from the viable cells were
analyzed for luciferase activity. The results, presented fold
change over control, indicated a significant (Po0.05)
increase in luciferase in the TMZ-resistant cells as compared
with vehicle treatment (Figure 3a). As each fragment
contained the first 250 bp of the Cx43 gene, we concluded
that this fragment was important for the activation of the
reporter gene during TMZ treatment.
TMZ activated AP-1. The 250-bp fragment within the 50
regulatory region of GJA1 (Cx43) was identified as the active
region in the TMZ-resistant cell lines (Figure 3a). To
understand this further, we scanned the region for transcrip-
tional factor binding site. We selected a potential AP-1-
binding site (Figure 3b) because this site has been shown to
induce Cx43 in other tissues.22 We transfected the GBM cells
with a reporter gene that was under the control of six AP-1
tandem repeats and then treated the transfectants with
200mM TMZ. At 24, 48 and 72 h, we analyzed cell extracts
for luciferase activity. In both cell lines, luciferase levels were
significantly (Po0.05) increased at 48 h, whereas this
consistency was not seen at the 24-h time point
(Figure 3c). The results indicated that TMZ treatment led to
the activation of AP-1 in the GBM cells and this occurred
after 48 h TMZ treatment. Based on these results, we
proposed that AP-1 was activated about 24 h before TMZ
resistance.20
Interaction of AP-1 with endogenous GJA1 (Cx43). AP-1
seemed to have a role in Cx43 expression (Figure 3). As we
did not mutate the AP-1-interacting sites, the studies could
not definitively state that this region was responsible for the
increase in Cx43 transcription. We however used different
methods to link the pathways in the activation of AP-1 in
TMZ-resistant GBM cells.
AP-1 is a heterodimeric transcription factor composed of
c-Fos and c-Jun proteins. In addition, c-Junmembers can also
homodimerize.23 We therefore asked which subunits were
activated in the TMZ-treated U87 and T98G cells. We treated
the cells for 72 h with 200mM TMZ and then performed
intracellular labeling for phospho-c-Jun and -Fos. Flow
cytometric analyses indicated increased phospho-c-Jun in
both cell lines and minimum phospho-c-Fos (Figures 4a and b,
Supplementary Figure S2).
We next asked whether AP-1 interacted with endogenous
GJA1 (Cx43) in TMZ-resistant GBMusing chromatin immuno-
precipitation (ChIP) assay with anti-c-Jun and PCR with
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primers spanning the AP-1 site. Analyses of the PCR product
on agarose gel electrophoresis showed a bright band for TMZ-
resistant GBMs. This indicated that AP-1 interacted with the
Cx43 gene in the TMZ-resistant GBM cells (Figure 4c).
ERK and JNK in AP-1 activation. The results shown thus
far indicated that AP-1 was important for the expression of
Cx43 in the TMZ-resistant GBM cells. We next asked
whether the activation of AP-1 was because of upstream
Figure 1 Increased Cx43 in TMZ-treated GBM cells. (a) U87 and T98G cells were treated with 200mM TMZ. After 72 h, real-time PCR was performed with primers specific
for Cx26 (left) and Cx43 (right). (b) Whole-cell extracts were prepared from U87 and T98G cells treated with TMZ for 72 h, and then analyzed by western blots for Cx26, Cx32
and Cx43 (left). The normalized band densities for Cx43 protein is shown at right. (c) RNA from low-passage cell lines from a patient with recurrent GBM (TMZ resistance
BT164) and a naive patient (TMZ-sensitive BT145) were studied by real-time PCR for Cx26, Cx32 and Cx43 mRNA. The data are shown for the mean relative fold
expression±S.D., n¼ 4. (d) Whole-cell extracts from BT145 and BT164 were analyzed by western blot for Cx43. (e) TCGA level 3 with4500 GBM tissues was used to verify
the expressions of Cx26, Cx32 and Cx43 expressions. The results are shown as the mean±S.D. for all samples within the database.* Po0.05 versus Cx26 or Cx32
Cx43 in chemoresistant GBM
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activation of JNK and ERK1/2. These kinases are down-
stream of EGFR signaling, which is commonly associated
with GBM pathology.24 Thus, auto-transphosphorylation of
EGFR could activate AP-1 via ERK1/2 and JNK. We
performed western blot for total and phospho-ERK and -
JNK in untreated (time 0) and TMZ-treated GBM cells.
Specific antibodies were used to detect unphosphorylated
and the phosphorylated forms (total). The results showed
time-dependent increases in phospho-ERK and -JNK
(Figure 4d and Supplementary Figure S2).
EGFR1-JNK-ERK-AP-1 axis in Cx43 expression. Studies
were conducted to determine whether JNK-ERK-AP-1 axis
(Figure 4d) was involved in Cx expression in the TMZ-resistant
GBMs. Specific pharmacological inhibitors blocked JNK,
ERK1/2 and EGFR activation. The activation of EGFR kinase
was inhibited by pretreating GBM cells with Erlotinib for 24h.
Similarly, the cells were pretreated with PD98059 to block
ERK1, SP600125 to inhibit JNK and U0126 to block the effect
of ERK1/2. The cells were treated with 200mM TMZ for 72h
that were the parameters of resistance. Whole-cell extracts
were analyzed by western blot for Cx43,  32 and  26. If the
inhibitors sensitized the GBMs to TMZ this would reduce the
number of GBMs. As the housekeeping b-actin was reduced,
we normalized each lane of Cx to b-actin (Figure 4e).
The lanes labeled as vehicle represent the control with
the inhibitors and TMZ treatment. As expected, the bands
were bright as the GBMs retained resistance (Figure 1b).
In contrast, cells treated with the kinase inhibitors
resulted in decreased Cx43 (Figure 4e and Supplementary
Figure S2).
Increased activation of EGFR in TMZ-resistant GBM
cells. EGFR signaling has been associated to Cx43
expression.25 As Cx43 was increased in the TMZ-resistant
GBMs (Figure 1), we asked whether this was caused by
EGFR activation as a large number of GBM patients showed
increased/activated EGFR.26 GBMs were treated with
200mM TMZ for 72 h or vehicle (untreated) and then
analyzed for surface EGFR by flow cytometry. Phosphory-
lated EGFR was increased by two- to three-fold in the TMZ-
resistant cells (Figure 5a, open histogram for resistant cells).
The studies strongly suggested that activated EGFR was
involved in Cx43 expression (Figure 4e). We therefore
performed cause–effect analyses by activating EGFR with
exogenous rhEGF in sera-free media containing 200 mM TMZ
and exogenous rhEGF (IC50¼ 50 ng/ml). After 72 h, whole-
cell extracts were studied for Cx43 by western blot. The
results showed significant (Po0.05) increase in Cx43 protein
in the presence of rhEGFR as compared with untreated/sera-
free GBM cells (Figure 5b, Supplementary Figure S3). The
specificity of EGF was tested by blocking the effect of EGFR
with FDA-approved anti-EGFR chimeric monoclonal antibody
(Cetuximab) (Figure 5b, right lanes).
Figure 2 Cell viability of TMZ-treated Cx43 knockdown GBM cells. U87 and T98G were transfected with Cx43-targeted siRNA or a non-targeting siRNA (Negative Control,
Neg Ctrl). The cells were analyzed by real-time PCR for Cx43 mRNA (a) and whole-cell extracts in western blot with anti-Cx43 (b). The knockdown cells, Neg Ctrl and
untransfected cells were treated with 200mM TMZ. After 72 h, the cells were studied for viability using the CytoTox 96 LDH release. The results are presented as mean±S.D.
of triplicates from each of four independent experiments (n¼ 12).*Po0.05 versus Neg Ctrl and untransfected cells
Cx43 in chemoresistant GBM
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The use of Cetuximab in sera-free media indicated that
EGFR is involved in Cx43 expression (Figure 5b). We
therefore repeated the studies in which TMZ-resistant GBM
cells were cultured in sera-containing media. The specificity
for EGFR was studied with different amounts of Cetuximab.
We did not use Erlotinib to block the kinase activity of EGFR
but selected Cetuximab because it competed with EGF. The
EGF can be present in the sera or produced by the resistant
GBM cells. Thus, Cetuximab will prevent autocrine and
paracrine stimulation of EGFR.
As expected, in the absence of Cetuximab (experimental
point 0), the bands for Cx43 was bright, which is consistent
for the TMZ-resistant cells (Figures 1b and 4e). However,
in the presence of Cetuximab, the bands for Cx43 were
decreased as compared with parallel cultures without
Cetuximab (Figure 5c, 0 a-EGFR; Supplementary
Figure S3). Interestingly, the decrease in the bands also
correlated with the disappearance of the lower bands,
which are generally indicative of phosphorylated Cx43.27
The results with Cetuximab were specific because similar
studies with an unrelated chimeric monoclonal anti-IgE
(FDA approved, Omalizumab) did not change the bands
for Cx43 (Figure 5c, left panels and Supplementary
Figure S3). Together, the studies showed a role for EGFR
signaling in the expression of Cx43 in the TMZ-resistant
GBM cells.
Dye transfer between GBM cells. As the resistant GBM
cells expressed Cx43, we asked whether the Cx43 was
functional with respect to the formation of GJIC between the
resistance GBM cells. Resistant GBM cells were established
by treating the cells with 200mM TMZ for 72 h as described.20
The resistant GBM cells were cocultured at 1:1 ratio of
unlabeled and CMTMR (Texas Red)-labeled. Negative
controls are represented as unlabeled GBM cells and
positive controls as labeled GBM cells alone. After 72 h,
dye transfer was assessed by fluorescence microscopy and
flow cytometry. As compared with the initial 50% labeled cells
by 72 h, 490% of the cells contained the CMTMR dye. This
indicated that the dye was transferred from one cell to the
other (Figure 6, Supplementary Figure S4). Parallel studies
with 1-octanol prevented the dye transfer, indicating speci-
ficity of GJIC. In four different experiments, the transfer of
dye was 480% efficiency between the TMZ-resistant GBM
cells. Representative transfer shows 83.2% for U87 and
98.8% for T98G (Figure 6a).
Discussion
This study reported on increased expression of Cx43 in TMZ
resistance GBM cell lines and low-passage cells (Figures 1
and 2). TMZ induced Cx43 transcription by an increase in
EGFR that activated MAPK-AP-1 (Figures 3–6). The findings
Figure 3 Effect of TMZ on the 50 regulatory region of GJA1 (Cx43). T98G and U87 cells were transfected with luciferase reporter vectors with various inserts, upstream of
the transcriptional initiation site of the GJA1 50 regulatory region.27 The transfectants were treated with vehicle or 200mM TMZ for 72 h. Whole-cell lysates from the viable cells
were analyzed for luciferase activity. The relative expression in luciferase activities are presented as the mean±S.D. The data represent triplicates from four independent
experiments, n¼ 12 (a). Shown is the AP-1 site within the 50 regulatory region Cx43 (GJA1) (b). GBM cell lines were transfected with a reporter vector containing AP-1
Tandem Repeats. The transfectants were treated with 200mM TMZ. After 72 h, whole-cell extracts were studied for luciferase levels. The results are presented as
mean±S.D. of triplicates in four independent experiments, n¼ 12 (c). *Po0.05 versus vehicle
Cx43 in chemoresistant GBM
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were supported by the data in TCGA (Figure 1e). We have
analyzed the chemoresistance to TMZ in long-term- (43
months) and short-term (72 h)-treated GBM cells (unpub-
lished data). The treatment led toB40% cell death in both the
short- and long-term exposure to TMZ; hence the 72-h time
period was selected to induce TMZ resistance.
The ChIP assay combined with pharmacological inhibitors
supported a role for AP-1 in Cx43 induction. The present
Figure 4 EGFR-mediated activation of AP-1 in TMZ-treated GBM cells. (b) U87 and T98G cells were treated with 200mM TMZ. After 72 h, the viable cells were analyzed
by flow cytometry for phospho (p)-c-Jun (a) and p-c-Fos activation. The dark histograms represent untreated cells and the gray histograms, TMZ treatment. The MFI of each
histogram is depicted with an arrow. (c) ChIP analyses were performed for AP-1 binding to endogenous Cx43 using TMZ-resistant GBM cells. The complex was precipitated
with anti-c-Jun. Shown are the PCR of the precipitated gDNA with primers spanning the AP-1 site. (d) Western blots were performed for the upstream activators of AP-1
activation, pERK and p-JNK using whole-cell extracts from untreated (Time 0) and timeline treatment of U87 and T98G with 200mM TMZ. The timeline studies occurred at 12 h
intervals up to 96 h. (e) GBM cells were pretreated different pharmacological agents along the EGFR signaling pathway. After 24 h, the cells were washed and then exposed to
200mM TMZ for 72 h. Whole-cell extracts were analyzed by western blots for Cx26, Cx32 and Cx43
Cx43 in chemoresistant GBM
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report did not use the reporter gene constructs with mutant
AP-1 site. Such studies are planned to fully understand how
increased Cx43 causes chemoresistance in GBM cells. TMZ-
mediated increase in Cx43 transcription in the GBM cells
would allow the formation of GJIC for exchange of molecules
across gap junction (Figures 6a and b). We reported on the
transfer of miRNAs from chemoresistant GBM cells through
exosomes.20 As miRNAs can be passed from one cell to
another throughGJIC,14 our findings could be anothermethod
by which resistant GBM cells survive TMZ treatment.
The resistance of GBM to TMZ with tumor relapse within
months is important to understand the mechanism of
resistance.28 This study identified potentially new methods
to combine with current treatments for GBM. We showed how
TMZ could cause GJIC for the passage of small molecules
(o2 kDa) such as miRNA.29 In the CNS, astrocytes abun-
dantly express gap junctions for cellular maintenance and
regulation.30 Cx43 is the main contributor of GJIC formation in
astrocytes.16 Astrocytomas commonly overexpress the same
gap junction proteins as shown here for GBM, which is World
Health Organization grade IV astrocytomas.31 The identifica-
tion of Cx43 as key in the resistance of GBM to TMZ is in line
with the argument that this could be important for themigration
of GBM.18
The systematic approach used in this study showed a role
for Cx43 in the resistance of GBM to TMZ. The significance of
our findings in future studies was demonstrated in our final set
of studies in which we showed functional GJIC between GBM
cells by fluorescent dye transfer (Figure 6). The importance of
the gap junctional protein in TMZ resistance was underscored
in studies in which we knocked downGJA1 and demonstrated
an increase in cell death to TMZ (Figure 2). Together, these
experiments supported a role for Cx43 as a protector against
TMZ treatment.
We analyzed the region within the GJA1 that showed
sensitivity to TMZ using a reporter gene system.27 These
studies indicated that TMZ can activate the region of GJA1
close to the transcriptional start site (Figure 3). The region
contained an AP-1 site (þ 44/þ 50), which was shown to be
functional with regard to Cx43 expression.22 Indeed, we
showed that the AP-1 subunit, c-Jun, was phosphorylated
after TMZ exposure (Figure 4d). This correlated with the ability
of AP-1 to bind endogenous GJA1, as indicated by the ChIP
assay (Figure 4c).
Overall, the findings showed a role for AP-1 in the induction
ofMDR1 in resistant GBM cells. Thus, it is expected that AP-1
transcription should be increased before full resistance, which
occurs with 72 h TMZ treatment. Indeed, timeline studies
using a reporter gene under the control of AP-1 repeats
showed an increase in AP-1 activity at 48 h of TMZ treatment
(Figure 3c). This correlated with an increase in the phos-
phorylated form of AP-1 subunit at 72 h (Figure 4a). The
phosphorylation of c-Jun is downstream of activated ERK1/2
and JNK (Figure 4d). These activated proteins were involved
in Cx43 expression (Figure 4e). As ERK1/2 and JNK can be
activated by the EGFR, we focused on the involvement of
EGFR on TMZ resistance of GBM cells. This data indicated an
increase of functional EGFR expression, resulting in an
increase in Cx43 expression (Figure 5). These findings
suggested that EGFR signaling could be important even in
caseswhere the receptor was not shown to bemotivated. As a
monoclonal antibody to EGFR was approved as Cetuximab
by the FDA, the findings show promise for the treatment of
GBM. These findings underscore the importance of taking
another review on the pathogenesis of EGFR in the biology of
GBM. In our ongoing studies, we have performed in vivo
studies in which we were able to reverse TMZ resistance with
an inhibitor of EGFR kinase. The findings will be the subject of
a separate paper.
Data derived from4500 GBM tissues in TCGA supported
the in vitro findings on increased Cx43 GBM cells as
compared with Cx26 and Cx32 (Figure 1e). The findings were
validated with two low-passage cell lines derived from an
Figure 5 Effects of EGFR signaling on Cx43 expression. (a) Flow cytometry
was performed for cell surface expression for EGFR with untreated and TMZ-
resistant GBM cells. Resistance was established with 200mM TMZ for 72 h. The
solid histogram represents untreated cells and the open histogram represents
treated cells. The MFI of each histogram is shown with an arrow. (b) GBM cells were
treated in sera-free media with 25 and 50 ng/ml of rhEGF. In parallel, the 50 ng/ml
point also contained Cetuximab at 1/500 dilution. In parallel, the cells were
stimulated with 10% FBS alone and with serum-free medium alone. At 24 h, whole-
cell lysates were analyzed by western blots for Cx43. (c) TMZ-resistant U87 and
T98G cells were established with 200mM TMZ, in the presence or absence of
Cetuximab (a-EGFR) or Omalizumab (a-IGE). Each antibody was used at the
following final dilutions: 1 : 500, 1 : 2500 and 1 : 5000. After 72 h, whole-cell lysates
were analyzed by western blot for Cx26, Cx32 and Cx43
Cx43 in chemoresistant GBM
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untreated patient (BT145) and TMZ-resistant (BT164) GBM
patient. More importantly, the two low-passage cell lines
supported the expression of Cx43 on TMZ-resistant cells. As
BT145 was never treated, it is assumed that this cell line was
TMZ sensitive. Although the mRNA for the three Cxs were
increased in the resistant line, only Cx43 protein was
increased in the resistant BT164 cells and the resistant
established GBM cell lines (Figure 1).
Figure 6c summarizes the main findings in this study. We
showed EGFR signaling as essential for the increase in Cx43
in the TMZ-resistant GBM cells. The resistant GBM cells
expressed higher level of EGFR (Figure 5a). However, it was
unclear whether the increase was caused by TMZ. This
question requires a separate study to understand how TMZ
induces EGFR and how to discriminate between unpho-
sphorylated and phosphorylated EGFR. As we demonstrated
GJIC in the chemoresistant GBM cells, the findings indicated
that EGFR signaling could be significant for intercellular
communication and might explain how the resistance of one
cell may be spread to other similar cells. The initial studieswith
immortalized cell lines were supported with other sources of
GBM: array databases with patients’ tissues and with low-
passaged cell lines from GBM. The use of pharmacological
methods to decrease Cx43 was encouraging, as this strategy
could be explored for new methods to treat GBMs. Direct
targeting of Cx43 might be toxic as neural cells express high
level of Cx43.32 On the other hand, this study opens the ‘door’
to research that could lead to the identification of molecules
that are exchanged between the resistant GBM cells.
Their identity could be new drug targets. We showed that
mesenchymal stem cells can be used to deliver anti-miRNA to
resistant GBM cells.20 Similar methods could be used once
future studies identified the molecules that are exchanged
through GJIC. The proposed method with stem cells have
been used to transfer prodrug to brain tumors.33
Materials and Methods
Cell lines. U87 and T98G World Health Organization grade IV GBM cells were
purchased from American Type Culture Collection (Manassas, VA, USA) and then
expanded as per manufacturer’s instructions.
BT145 (primary GBM) and BT164 (recurrent GBM) glioma cell lines were derived
from surgical resection material acquired from patients undergoing surgery at the
Brigham and Women’s Hospital on an Institutional Review Board approved protocol
as part of the DF/BWCC Living Tissue Bank. Briefly, tumor resection samples were
mechanically dissociated, and tumorspheres were established and propagated in
Human NeuroCult NS-A Basal media (StemCell Technologies, Vancouver, BC,
Canada) supplemented with EGF, FGFb and heparin sulfate.
Reagents and antibodies. All tissue culture media were purchased from
Gibco (Grand Island, NY, USA), and fetal calf serum was purchased from Hyclone
Laboratories (Logan, UT, USA). Recombinant human EGF was obtained from
R&D Systems (Minneapolis, MN, USA). For fluorescent imaging, CellTracker
Orange CMTMR [5-(and-6)-(4-chloromethyl) benzoyl)amino)tetramethylrhodamine]
was purchased from Invitrogen (Carlsbad, CA, USA).
Mouse anti-Cx43, anti-Cx32 and anti-Cx26 were purchased from Invitrogen and,
mouse anti-b-actin mAb, HRP-anti-rabbit and HRP-anti-mouse IgG from Cell Signaling
Technology (Billerica, CA, USA). EGFR blocking humanized antibody (Cetuximab) and
humanized IgE (Omalizumab) were kind gifts from Roche (Nutley, NJ, USA).
EGFR signaling inhibition was achieved using the following inhibitors: Erlotinib
(10mM, IC50¼ 5–20mM), SP600125 (25mM, IC50¼ 10–50mM), PD98059 (5 mM,
IC50¼ 5–10 mM) and U0126 70mM, IC50¼ 50–70mM). SP600125, PD98059 and
U0126 were purchased from Sigma-Aldrich (St. Louis, MO, USA) and Erlotinib was
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Figure 6 GBM cells form functional gap junctions. (a) Ten5 unlabeled U87 or T98G cells were cocultured for 72 h with ten5 CMTMR-labeled (Cell Tracker Orange) cells
(center). Dye transfer was evaluated by flow cytometry. (b) A diagram shows TMZ-resistant GBM cells with activated EGFR, which phosphorylated JNK and ERK1/2 to activate
AP-1 for Cx43 expression
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Vectors. The GJA1 (Cx43) reporter gene (luciferase) contained inserts within
the 50 regulatory region. The reporter gene vectors were kindly provided by Dr. M
Kandouz, Wayne State University School of Medicine (Detroit, MI, USA). The
vectors were previously described.21 The pGL3 luciferase backbone vector
(Promega, Madison, WI, USA) served as vector control. AP-1 activity was
evaluated with pGL4.44[luc2P/AP-1 RE/Hygro, which is a 6x Tandem Repeat
Element of AP-1, upstream of luciferase (Promega).
Dye transfer. U87 or T98G cells (5 105) were seeded in six-well plates and
then incubated with 2.5mM of prewarmed CellTracker Orange CMTMR [5-(and-6)-
(((4-chloromethyl) benzoyl)amino) tetramethylrhodamine] (Life Technologies - Molecular
Probes, Grand Island, NY, USA). After the CMTMR enters the cells, it reacts with the
intracellular components and cannot exit the cells. Thus to ensure specificity, GJIC
studies are done in the presence of an inhibitor, 1-octanol. The cells were incubated
for 45 min at 37 1C in a CO2 incubator. After this, the media were removed and the
cells were washed three times with PBS. Fresh culture media were added to the
washed cells. The plates were incubated for 6 h and then subjected to a second
wash with PBS. After this, the labeled cells were cocultured with 5 105 unlabeled
cells. After 72 h, the cells were trypsinized, centrifuged at 500 g, resuspended in
0.5 ml of PBS and then immediately evaluated by flow cytometry for dye transfer.
Real-time RT-PCR. RNA was extracted with Trizol reagent (Invitrogen).
Reverse transcription was performed using the High Capacity cDNA Reverse
Transcription Kit (Life Technologies - Applied Biosystems, Grand Island, NY, USA)
in accordance with the manufacturer’s recommendation. Real-time PCR was
performed with 200 ng cDNA on a 7300 Real-Time PCR System (Applied
Biosystems). The initial incubation was at 50 1C for 2 min followed by 95 1C for
10 min. After this, the cycling conditions were as follows: 95 1C for 15 s and 60 1C
for 60 s, for 40 cycles. Primer sequences used in the PCR were: Cx26:
(F) 50-AGCTCTGCTCCCCTAAAG-30 (R) 50-TGTGTCCTCTGTGGAACC-30; Cx32:
(F) 50-GGCATTCTACTGCCATTG-30, (R) 50-TGGGGTGGAAACTAGGAT-30;
Cx43: (F) 50-TCGGGTTAAGGGAAAGAG-30, (R) 50-GCTCACTTGCTTGCTTGT-30;
b-actin: (F) 50-TGCCCTGAGGCACTCTTC-30 and (R) 50-GTGCCACCAGGGCAGT
GATCT-30. Primers were purchased from Sigma (St. Louis, MO, USA). The relative
expression was calculated using 2(Delta Delta C(T)), as previously described.14
Western blot. GBM cells were treated with 200mM TMZ or with vehicle.
After 72 h, whole-cell extracts were isolated with M-PER Mammalian Protein Extraction
Reagent (Thermo Scientific, Rockford, IL, USA). Cell extracts (3–7mg) were analyzed
by western blots, as previously described on 12% SDS-PAGE gels (Bio-Rad,
Hercules, CA, USA).27 Proteins were transferred to PVDF membranes (PerkinElmer,
Boston, MA, USA). The membranes were incubated overnight with primary antibodies
at final dilutions ranging between 1/500 and 1/1000. Primary antibodies were detected
by incubating for 2 h with HRP-conjugated IgG at 1/2000 final dilution. HRP activity
was assayed by chemiluminescence using SuperSignal West Femto Maximum
Sensitivity Substrate (Thermo Scientific). Membranes were stripped with Restore
Stripping Buffer (Thermo Scientific) and then reprobed with other antibodies.
Flow cytometry. The cell surface expression for EGFR was analyzed by flow
cytometry with 1/100 final dilution of anti-EGFR (Cetuximab with human Fc).
This was followed by incubation with 1/500 mouse anti-human IgG (bridging
antibody). A third incubation used 1/1000 FITC-conjugated goat-anti-mouse IgG.
The fluorescence intensity was determined with a FACS Calibur (BD Biosciences,
San Jose, CA, USA).
Cell death analyses. Lactate dehydrogenase (LDH) release assays
(Promega) studied cell death. The LDH assay was based on the disruption of
the cell membrane. The LDH assay was assessed at 72 h after TMZ treatment.34
We measured the conversion of Formazan (Red) using a Victor3V Multilabel Plate
Reader (PerkinElmer; Waltham, MA, USA) with an emission filter of 490 nm. The
results were normalized to complete cell lysis. This was aided by a lysis buffer
included in the LDH assay kit.
Analyses of the 50 regulatory region of GJA1. The minimal promoter
of the GJA1 gene was identified on the basis of the information in the NCBI
database (NC_000006.11). This region was identified as  250 bp, relative to the
transcriptional initiation site, and was also supported by luciferase activity (see
Results section). The 250-bp region was analyzed for potential transcriptional
binding regions using Genematix platform (Munich, Germany).
ChIP assay. ChIP analysis for AP-1-interacting site on the GJA1 gene was
performed using the ChIP-it Express Enzymatic Kit (Active Motif, Carlsbad, CA,
USA), as described.35,36 A ChIP-validated anti-c-Jun antibody was also purchased
from Active Motif. GJA1 isolation was confirmed by qPCR. Samples were isolated
during the exponential phase of synthesis as determined by qPCR and run on 1%
agarose gel. Although two bands were amplified from genomic input DNA, only the
upper band (200 bp) was isolated by ChIP. The upper band was confirmed to be
GJA1 PCR.
Transfection and reporter gene assay. U87 and T98G cells were
transfected with the GJA1 reporter gene constructs, using Effectene Transfection
Reagent (Qiagen, Valencia, CA, USA). After 72 h, protein lysates were obtained
using M-PER Mammalian Protein Extraction Reagent (Thermo Scientific), and
quantified for protein concentration (Bio-Rad). Luciferase activity was calculated as
per total protein and then presented as relative light units. The relative light units
was normalized to untreated lysates.
Statistical analysis. Data were analyzed using the Student’s t-test for two
comparable groups (control/experimental). A P-value o0.05 was considered
significant.
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